Renaissance Technologies LLC increased its position in EverQuote, Inc. (NASDAQ:EVER - Free Report) by 32.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 469,087 shares of the company's stock after acquiring an additional 116,100 shares during the period. Renaissance Technologies LLC owned about 1.33% of EverQuote worth $9,377,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in EVER. Geode Capital Management LLC lifted its position in EverQuote by 10.4% during the third quarter. Geode Capital Management LLC now owns 595,155 shares of the company's stock valued at $12,554,000 after purchasing an additional 56,114 shares during the period. Counterpoint Mutual Funds LLC grew its holdings in shares of EverQuote by 74.3% in the fourth quarter. Counterpoint Mutual Funds LLC now owns 38,053 shares of the company's stock worth $761,000 after acquiring an additional 16,217 shares during the period. Intech Investment Management LLC bought a new position in EverQuote in the fourth quarter valued at about $236,000. Barclays PLC grew its stake in shares of EverQuote by 331.2% during the 3rd quarter. Barclays PLC now owns 50,983 shares of the company's stock valued at $1,076,000 after purchasing an additional 39,160 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of EverQuote by 3,022.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 385,629 shares of the company's stock valued at $8,133,000 after purchasing an additional 373,280 shares during the last quarter. 91.54% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have commented on EVER. Needham & Company LLC upped their target price on shares of EverQuote from $30.00 to $38.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Canaccord Genuity Group cut their price target on EverQuote from $35.00 to $30.00 and set a "buy" rating for the company in a report on Monday, February 24th. Raymond James raised EverQuote from an "outperform" rating to a "strong-buy" rating and set a $35.00 price objective on the stock in a research report on Thursday, December 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of EverQuote from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.33.
Check Out Our Latest Research Report on EverQuote
EverQuote Stock Down 6.7 %
EverQuote stock traded down $1.53 during midday trading on Monday, reaching $21.28. 562,204 shares of the stock traded hands, compared to its average volume of 546,298. EverQuote, Inc. has a 12 month low of $16.63 and a 12 month high of $30.03. The stock's fifty day moving average is $24.35 and its 200-day moving average is $20.93. The stock has a market cap of $760.21 million, a P/E ratio of 62.59 and a beta of 0.77.
EverQuote (NASDAQ:EVER - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.15 by $0.18. EverQuote had a net margin of 3.31% and a return on equity of 13.94%. The business had revenue of $147.46 million during the quarter, compared to analyst estimates of $133.83 million. On average, equities analysts predict that EverQuote, Inc. will post 0.72 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director David B. Blundin sold 77,600 shares of the company's stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $28.67, for a total value of $2,224,792.00. Following the transaction, the director now directly owns 97,920 shares in the company, valued at approximately $2,807,366.40. This represents a 44.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John L. Shields sold 2,000 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $20.93, for a total transaction of $41,860.00. Following the completion of the sale, the director now directly owns 26,515 shares of the company's stock, valued at approximately $554,958.95. This trade represents a 7.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 181,607 shares of company stock worth $5,011,502 over the last three months. 29.79% of the stock is owned by insiders.
EverQuote Profile
(
Free Report)
EverQuote, Inc operates an online marketplace for insurance shopping in the United States. The company offers auto, home and renters, and life insurance. The company serves carriers and agents, as well as indirect distributors. The company was formerly known as AdHarmonics, Inc, and changed its name to EverQuote, Inc in November 2014.
Featured Articles

Before you consider EverQuote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EverQuote wasn't on the list.
While EverQuote currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.